

Short Course on Clinical Decision-Making for Drug-Resistant Tuberculosis 2019-2020

STUDENT HANDBOOK

Instituut voor Tropische Geneeskunde . Nationalestraat 155 . 2000 Antwerpen . België <u>http://www.itg.be</u> . Stichting van Openbaar Nut 0410.057.701 Tel +32-3-247 66 66 . Fax +32-3-216 14 31 . E-mail <u>info@itg.be</u>



Short Course: "Clinical Decision-Making for Drug Resistant Tuberculosis" (DR-TB)



Welcome to the short course "Clinical Decision Making for Drug Resistant Tuberulosis", in short DR TB. This guide provides some essential information about the course and your stay at ITM in Antwerp. We wish you a wonderful and enriching time at our Institute!

Table of content

1	Introduction	4
2	The course content	4
	2.1 General learning objectives	4
	2.2 Specific objectives:	4
	2.3 Programme	4
	2.4 Teaching and learning methods	6
	2.5 Admission requirements	6
	2.6 Selection criteria	6
3	Student assessment	7
4	Course evaluation	9
5	Course management structure	9
6	Practicalities	10

1 Introduction

Drug-resistant tuberculosis (DR-TB) is an important challenge for clinicians. With the introduction of molecular diagnostic tests, such as the Xpert MTB/RIF assay and Line Probe Assays, the notification of DR-TB is increasing and the time to diagnosis can be shortened, allowing earlier treatment initiation. Shorter treatment regimens (STR) of nine months duration are now also recommended by WHO, thus simplifying treatment for patients and National TB Programs alike. New and repurposed drugs, such as bedaquiline, delamanid, linezolid, and clofazimine, are increasingly available. Guidelines are being adapted frequently. Clinicians require training in the use of these new diagnostic tools, the interpretation of guidelines, and in making informed choices for treatment initiation and monitoring and in adequate and timely clinical decision making.

This blended course offers interdisciplinary and interactive training on clinical aspects of DR-TB diagnosis and care. It consists of a seven-week online training (8 hours/week) followed by ten days face-to-face.

The course is taught exclusively in English.

2 The course content

2.1 General learning objectives

TB clinicians improve clinical decision-making using locally available diagnostic tools and treatment options.

2.2 Specific objectives:

At the end of the course the student should be able to:

- 1. Define the problems with DRTB in their country in terms of occurrence, diagnosis and treatment, using available data;
- 2. Assess harm and benefit of clinical decisions in the field of DR-TB diagnosis and treatment;
- 3. Formulate contextualized evidence-based recommendations for the prevention, diagnosis and treatment of DR-TB for case studies from different contexts.

2.3 Programme

The course consists of an online and face-to-face (F2F) module. The F2F module is given at the ITM, Antwerp.

During the online module 7 different topics are being addressed. These topics are further developed during the F2F. Participants work on a case study during the online module. They present the case during the F2F and incorporate knowledge they have gained during the F2F lectures in their final presentation.

Online module	8 weeks between 18/02/2019 and 28/04/2019 (including a 2-week break)
Week 1	Introduction to the online course
Week 2	Epidemiology; know your epidemic
Week 3	Diagnosis 1; How to diagnose TB and rifampicin resistance
Week 4	Diagnosis 2; How to diagnose resistance to other drugs
Week 5	Clinical decision making 1; Measures of test performance
Week 6	Treatment 1; DR-TB drugs and regimens
Week 7	Treatment 2; DR-TB drugs and regimens in complex cases
Week 8	Clinical decision making 2; Harm, benefit, threshold for making a decision which regimen to use

Table 2.3.1: Timeline and topics of the online module

Table 2.3.2: Timeline and topics of the face-to-face module

Face-to-face module	10 days between 13/05/2019 and 24/05/2019
Day 1	Discuss case studies with teachers and adapt to fit oral presentation during one of the planned sessions
	Clinical epidemiology
Day 2	Performance of diagnostic tests DST: definitions and concepts Sample transport Xpert MTB/RIF - interpretation Whole genome sequencing – indications
Day 3	DST: interpretation, limitations and discordance Lab visit: phenotypic and molecular DST
Day 4	Models of DR-TB care Principles of constructing a TB-regimen Thresholds in clinical decision-making
Day 5	WHO MDR/RR-TB guideline 2019: interpretation Short treatment-regimen: indications, modifications, what if high resistance-prevalence MDR-TB programmes: model of care
Day 6	Operational research Multiple core-drugs in one regimen: pro and con Surveillance of RMP resistance
Day 7	Construct a standardize regimen (with core and add-on drugs): impact of initial resistance, practical experience New and repurposed TB-drugs
Day 8	Adverse events of TB-drugs
Day 9	Co-morbidities in MDR/RR TB patients Genotypic testing – epidemiological applications

	Pediatrics
Day 10	Evaluation: Final presentations of case studies

2.4 Teaching and learning methods

- Problem-based learning: During both the online and face to face part, case studies are used. As such, the learning experience fits as much as possible the problems experienced by participants in their programmatic setting. Moreover, face-to-face sessions often start with a case study presentation. Case studies are followed by an interactive debate between participants and experts. At the end of a session, the expert provides a lecture to complement the debate. As such the theory aligns well with the problems identified by participants.
- Flipped learning: During the online part course participants prepare for the face-toface debates. Most of the theory will be digested at home, which allows students to use the precious class time for interaction with peers and experts. Participants have access to guidelines and other sources of evidence for consultation, and gaps in the evidence base are identified. In addition, challenges and achievements in diagnosing and treating DR TB, as experienced by the participants, are discussed. The two-week days face-to-face builds further on the content addressed during the online part, and includes group discussions, case presentations, summaries of key learning points by students, and interactive lectures (didactic lecturing accounts for 30% of the contact hours).
- Social constructivism: Course participants will construct their knowledge through debates with peers and experts, and group work.

2.5 Admission requirements

The course targets clinicians working in the field of DR_TB.

- Participants should be holders of a university degree in medicine (min. 4 years, e.g. should be a medical doctor) equivalent to 240 ECTS (referred to as a Master degree in the European Union).
- Proficiency in English is required. If your university studies were done in English: you are exempted of a language certificate. If this is not the case: an officially recognised proficiency language certificate is mandatory. Required level for English: TOEFL paper-based 580, computer-based 230, Internet-based 88 or IELTS 6.5 (ITM Toefl Code 7727).
- To participate in the online and the face-to-face course, access to a computer and internet connection is required. We strongly suggest to use Mozilla firefox or Google Chrome in order to access our website (Internet explorer is not 100% compliant).
- Only if you want to apply for a DGD scholarship: at least two years of professional experience is required. (Other requirements for the DGD scholarship: please check http://www.itg.be/E/scholarships).

2.6 Selection criteria

Candidates will be selected based on the following criteria:

• Active work experience in DR_TB care

- Previous attendance in DR_TB courses
- Profile as shown in the Curriculum Vitae
- Motivation letter (including a description of the challenges in DR TB care you are confronted with and the commitment from own home institution in supporting your application)
- Two reference letters (including a description of the applicant's involvement in DR TB care)
- A written description of a case study that shows challenges with diagnosis and/or the treatment of DR-TB

3 Student assessment

Six assignments are considered for the final score; 5 from the online module, one from the F2F module. Three additional assignments are not scored.

Online assignment 1 (10 points)	Participants describe the DR-TB epidemic in their country, using indicators showing the DR-TB cascade. Maximum score if: all requested indicators were developed, the data are correctly interpreted and sources are mentioned
Online assignment 2 (10 points)	 Participants describe and assess the DR-TB diagnostic tests and algorithms available in their setting. Maximum score if: the flow of tests is listed + 1) the level of care at which tests are performed (primary, secondary, tertiary); 2) turnaround time, by test; 3) strong points and challenges (own experience); 4) approaches to overcome challenges are mentioned
Online assignment 3 (10 points)	Participants peer review the diagnostic algorithms presented by another course participant. Maximum score if: the peer review is conducted + 1) feedback on what applies to his/her own context, 2) + feedback on a possible way forward for the context that is reviewed
Online assignment 4 (10 points)	Participants contribute to the online discussion on experiences with new drugs and regimens. Maximum score if: contributions are new, and evidence-based, or supported by program data
Online assignment 5 (10 points) Face-to-face	Participants do a quiz on the interpretation of Xpert MTB/RIF and DST results and indications for new drugs and regimens Participants present their case study
assignment (50 points)	 Score of the jury is based on: 1. Description of the clinical case and problem statement (concise, clear, use of table) 2. Evaluation of the problem shown in the case study (clear, balance of harm & benefit of different options) 3. Formulation of lessons learnt related to diagnostic tests and treatment used in the case study (clear, lesson learnt is correct, use of data /evidence)

Table 2.2.1 Assignments included in the assessment

- 4. Formulation of recommendations for diagnostic tests and treatment for the future, considering lessons learnt from the course (clear, lesson learnt is correct, use of data /evidence)
- 5. Response to questions (clear, concise, correct, contextualized)

The face-to-face (F2F) module of the DR TB course builds further on the content of the online module. Therefore, active participation during the online module is key.

The minimum is to participate in 6 out of 7 discussions. Thus, particpants should score at least one point for 6 discussions. Moreover, every week a new assignment will be explained. All (!) assignments need to be submitted. Two assignments will be related to the elaboration of a personal project, the case study on diagnosis and/or treatment of a DR-TB case (for which you submitted a subject during your application for this course).

Participants who don't participate during the online module are not allowed to join the F2F in Antwerp, because the F2F builds on the online module (and plane tickets may be cancelled). Luckily this is very rare, as usually participation is very active.

4 Course evaluation

A **formal written and oral evaluation** is organized at the end of the course. The participation to this formal evaluation is mandatory. The results of this evaluation are discussed with individual lecturers, and major problems or cross-cutting issues are dealt with in the steering group of this course.

Contacts with former participants are also a way to receive continuous feedback on the relevance of the programme. This can either be through informal e-mails or through a formal **alumni survey**. We may at times ask for your opinion on a certain change in the programme we are considering. Since 2019 we involve former participants as faculty during the online course.

As the core of the course faculty is very stable, lessons learnt from previous editions are easily implemented. Moreover, a lot of faculty attends sessions given by colleagues. Two person attend all the sessions. This allows fine-tuning key messages and prevents sharing contradictory messages.

Through an alumni e-newsletter and the ITM magazine, we also keep our alumni informed on what's happening at ITM. You are most welcome to share your experiences or thoughts related to the course, as well as your field experience with your colleagues. The e-newsletter published quarterly is made available through the ITM website.

5 Course management structure

The course is organized by the Department of Clinical Sciences and by the Department of Biomedical Sciences of the Institute under the supervision of its educational coordinator: Dr. (mzolfo@itg.be).

The management of the course is in the hands of the course coordination team:

Course leaders:

Prof dr. Lutgarde Lynen, llynen@itg.be,
 Unit of HIV/AIDS and Infectious Diseases, Department of Clinical Sciences

Prof dr. Bouke De Jong, bdejong@itg.be,
 Unit of Mycobacteriology, Department of Biomedical Sciences

Remark: Prof Lynen and Prof De Jong will yearly alternate to take the role of course leader

Course coordinator:

- Department of Clinical Sciences: Tom Decroo, tdecroo@itg.be;
- Department of Biomedical Science: Pauline Lempens, plempens@itg.be;

Course secretary:

- Department of Clinical Sciences: Jasmien Adams, jadams@itg.be
- Department of Biomedical Science: Nadia Ehlinger, nehlinger@itg.be

The **course coordinator** remains at your disposal for any support on academic and programmatic aspects (course content). They ensures the information flow between lecturers and participants and liaises with the **course leader** and the educational coordinator and Govert Van Heusden, ITM Academic Coordinator regarding the internal quality assurance of the course.

<u>The course secretary</u> takes care of all **administrative issues**, such as certificates, attestations, student cards, electronic badge, copies of lectures notes, logistics for lectures and group work. For advice on cultural and social events in town or on addresses for medical help or other matters you can contact the Student Service: <u>studdienst@itg.be</u>.

The **academic coordinator**, <u>Govert Van Heusden</u>, is also the 'ombudsman' for participants of all courses, dealing with major complaints. You can contact him by e-mail: <u>gvheusden@itg.be</u> or tel: 03 247 62 33.

6 Practicalities

ITM-identification card & electronic badge

Each student receives an electronic badge to allow access to ITM's buildings, departments and bicycle parking. If you lose the electronic badge, you should immediately inform the course secretariat. A new electronic badge costs 20 euros. The electronic badge should be returned at the end of the course; if not, there's a 20 euros fine.

The student card is your ITM-identification card, and also gives you discounts in our Karibu Cafetaria and for cultural events throughout Belgium.

You need to have both badges with you at all times when at the Institute!

ITM access

Class rooms, laboratory practice rooms and group work rooms are spread over two buildings: Campus Nationalestraat and Campus Rochus.

The Institute is open from 8:00 till 19:00 hrs.

If you wish to study late at the Institute during the week, you can book a room* in the main building Nationalestraat until 21:00 hrs.

During weekends, you can book a room in the main building Nationalestraat from 9:00 till 17:00 hrs.

You can't stay at Campus Rochus after 19:00 hrs and you don't have access to Campus Rochus during weekends.

There are three bicycle parkings: on the corner of Nationalestraat/Kronenburgstraat, in the corner of the Campus Rochus garden and across Campus Rochus at n° 40. Access is only possible with an electronic badge, but bikes should still be locked individually. Bicycles have to be parked appropriately and allow free passage.

*Only Room C and Computer Room will be made available and should be booked at the reception Nationalestraat. Rooms can only be used for studying, with respect for other students.

Course venues

Leave classrooms clean and tidy. Don't leave anything on the tables, don't leave personal belongings. Use the big bins in the corridors. When smoking in the garden, don't leave cigarette butts on the terrace, on the grass or in the arbors: there are ashtrays at the different entrances to the building. Food nor beverages are allowed in the classrooms. Tables, chairs, flipcharts, black boards etc. can't be moved from the class rooms. Garden furniture should be put back on the terrace, after use on the grass.

In case of fire alarm, you leave the institute immediately through the nearest exit and from a group across the street. Leave the class room by the shortest way. Don't linger but don't run, don't take the elevator. Under no circumstances you should go back if you think you have forgotten something. Once outside and across the street, a staff responsible will check on you and give further instructions.

<u>Attendance</u>

Lecturers have a lot to share: please come to class in time!

Attendance is expected at all obligatory course sessions. Attendance to the courses is an essential part of the learning process.

Turn off your mobile phones during courses.

All documents are placed on Moodle, our open-source platform. Students are expected to **consult it on a daily basis**, given the regular updates.

If documents have to be read before a lecture, you are notified by e-mail.

Students keep access to Moodle until three years after the course. However, we advise you to download everything during the course: internet will not always be accessible when working abroad in the future.

A printout of the timetables of the upcoming week is posted at the entrance of the secretariat and should be checked regularly for eventual last minute changes which could not be communicated anymore by e-mail or Moodle.

Each student has an individual tray. Your tray is the one above – and not under - your name. These trays can't be used to store personal belongings, food or beverages.



ANNEX 1. Timetable example

	13/05 - INTRO	14/05 - DST	15/05 - DST	16/05 - TT / CDM	17/05 - STR
nr of case studies	2	1	3	3	3
	9:00-9:30: Introduction to the course	Learning points of the previous day	Learning points of the previous day	Learning points of the previous day	Learning points of the previous day
9:00-9:30	all teachers, Student Service	P. Lempens, Madelon, panel	P. Lempens, Madelon, panel	P. Lempens, Madelon, panel	
	Group 1 & 2: admin issues	DST1: definitions and concepts	DST5: Interpretation of phenotypic and genotypic DST	PRO1: MDR-TB programmes	RX2 - WHO guidelines
	Group 3 & 4: improve Ppt case study (Jan, Pauline, Tom,	Frequently used terms (proportion method, MIC, ECOFF,	results 1 case study: Brenda	Evidence on model of care for MDR-TB: community-	1 case study
	Anita, Madelon)	clinical breakpoints, molecular genetics,) (Pauline)	Methods for DST - indications, accuracy, interpretation,	delivery, task shifting, (Anita)	Evidence-base of 2019 MDR-TB guidelines - a closer look
9:30-11:00			EP samples, PED samples, TAT (Leen)	1 case study	(Armand)
5.50-11.00					
11:00-11:15	BREAK	Panel: B. de Jong, L. Rigouts BREAK	Panel: B. de Jong, L. Rigouts BREAK	Panel: A. Mesic BREAK	Panel: Gunta, Anita BREAK
	Group 3 & 4: admin issues			RX1: STR	PRO2: MDR-TB programmes
	Group 1 & 2: Improve Ppt case study (Jan, Pauline, Tom,		1 case study: Paidamovo Extra case	1 case study	Lessons learnt from stepwise implementation of new
	Anita, Madelon)	review of strips (Pauline - new lecture)	study: Aung Ko Ko Myanmar	Principles for constructing a tuberculosis treatment	drugs and regimens and care delivery in KNCV TB
11:15-13:00	Paried, mutclon y	review of surps (r dunite - new rectarcy	Limitations of DST (Bouke)	regimen + exercises (Tom)	programs (Gunta)
				- Charles (1011)	1 case study
		Panel: B. de Jong, L. Rigouts	Panel: B. de Jong, L. Rigouts	Panel: A. Mesic	Panel: Armand, Anita
13:00-14:00	LUNCH	LUNCH	LUNCH	LUNCH	LUNCH
	,			CDM2: Thresholds for clinical decision-making in the field	
	Pre- and post-test probability of disease - excel engine	1 case study: Akwuadikanwa			STR in settings with low or high prevalence of resistance
	(Lut)	Differences between Xpert and Xpert Ultra	INH and FQ resistance: DST results are not binary	1 case study	to FQ and/or 2LI (Anita)
14:00-15:45	1 case study	A critical view on the Xpert technology (Emmanuel	(Pauline)		1 case study
		André)			
	Panel: B. de Jong; Manu	Panel: B. de Jong, L. Rigouts	Panel: B. de Jong, L. Rigouts	Panel: A. Mesic Manu	Panel: Armand, Gunta
15:45-16:00	BREAK	BREAK	DST8: Lab visit and hands-on phenotypic DST	BREAK	BREAK
	CDM1: Clinical epidemiology	DST4: Mutations from target- or whole genome	interpretation	CDM2: Thresholds for clinical decision-making in the field	RX4: STR
	Pre- and post-test probability of disease - excel engine	sequences	(Bouke, Leen, Pauline)	of DR-TB	STR: indications & modifications (Armand)
	(Lut)	Interpretation and challenges (Conor Meehane)		Harm & benefit of a decision to test, and a decision to	
16:00-17:00	1 case study			treat, concepts of test threshold and treatment threshold	
				(Lut)	
	Panel: B. de Jong; Manu	Panel: B. de Jong, L. Rigouts		Panel: A. Mesic, Manu	Panel: Anita, Gunta
ROOM: ROCHU	IC WEET	ROOM C	ROOM C	· · · · ·	


Clinical Decision-Making for Drug Resistant Tuberculosis (DR TB) 2019-20


	20/05 - CDM	21/05 - XDR	22/05 - AE	23/05 - COM & PED	24/05 - Evaluation
nr of case	0		3	4	
studies	Ť	4	, and the second s		
9:00-9:30	Expectations for the last days of the course P. Lempens, Madelon, panel	Learning points of the previous day P. Lempens, Madelon, panel	Learning points of the previous day P. Lempens, Madelon, panel	Staying connected after the course? P. Lempens, Madelon, panel	Case study presentations (1/3)
	DST9: Hands-on LPA interpretation in the classroom	RX6: Construct a standardized regimen with core and add		COM2: co-morbidities	
		on SL drugs		1 case study	
		1 case study	Adverse events of the 9-M regimen: monitoring and		
		Impact of initial resistance on the outcome of standard	management (Alberto)		
9:30-11:00		regimens (Armand)			
		Panel: A. Mesic, A. Piubello	Panel: A. Mesic	Panel: A. Piubello	Panel: A. Piubello, A. Van Deun, G. Dravniece, G. Groenen
11:00-11:15	BREAK	BREAK	BREAK	BREAK	BREAK
		RX7: Construct a standardized regimen with core and add		Referral genotypic testing	Case study presentations (2/3)
	presentation of success and failures (Anita & Alberto)	on SL drugs	1 case study Audiometry: significance, measurement, and clinical	MIRU-VNTR & WGS: principles & indications (Howard)	
	debate	1 case study MDR-TB treatment programme in Niger (Alberto)	implications (Alberto)	1 case study	
11.15 12.00		Experiences with modifications to the STR (Alberto)			
11:15-13:00		,			
	Panel: Bouke	Panel: A. Mesic, A. Van Deun	Panel: A. Mesic	Panel: A. Piubello, A. Mesic	Panel: A. Piubello, A. Van Deun, G. Dravniece, G. Groenen
13:00-14:00	LUNCH	LUNCH	LUNCH	BREAK - studying at ITM	PHOTO + LUNCH
	PRO3: DR survey - novel designs (Leen)		RX9: New and repurposed DR-TB drugs	PED1: pediatric DR-TB care	14:00-15:15: Case study presentations (3/3)
		RX8: Construct a standardized regimen with core and add-	New and repurposed drugs (Anita)	DR-TB in children (Jay Achar)	
		on SL drugs 1 case study			
14:00-15:45		Modified shorter standardized regimens for pre-XDR and			
		XDR-TB (Alberto)			
	Panel: B. de Jong, A. Van Deun, Alberto	Panel: A. Mesic, A. Van Deun	Panel: A. Mesic		Panel: A. Piubello, A. Van Deun, G. Dravniece, G. Groenen
15:45-16:00	BREAK	BREAK	BREAK	BREAK	15:15-15:30: BREAK
		AE3: AE of DR-TB drugs QT and QTc: significance, measurement, and clinical	COM1: co-morbidities Co-morbidities (Anita)	PED2: pediatric DR-TB care 2 case studies	15:30-16:30: Evaluation
	surveillance, now to prevent resistance (Armanu)	implications (Alberto)	1 case study	2 Case studies	
16:00-17:00		1 case study			
	Panel: A. Van Deun; Alberto	Panel: A. Piubello, A. Van Deun	Panel: A. Piubello	Panel: Pediatrician, A. Piubello, A. Mesic	C. Kiyan, M. Stevens, M. Zolfo, G. van Heusden
ROOM: ROCH	LIC MEET				16:30-18:30: Closing ceremony
ROOM: ROCH	US WEST				




ANNEX 2. Study guide eDRTB 2019-20

HOW TO LOGIN TO OUR WEBSITE







Here are some icons that you might need to be familiar with



Glossary

Pre-test or Post-test

Upload your assignment



Discussion forum



Participants

Repository

21

Clinical Decision-Making for Drug Resistant Tuberculosis (DR TB) 2019-20

How to use the discussion forum?




During the introduction week, only one forum, Presentation forum, will be open and you will be asked to post a presentation of yourself in this forum.

The forum can be accessed through a link in the right menu(see picture). or a link on each module Every week new discussions will be started, linked to the module of the week. Discussions in the forum are organised by topic. If you open a specific forum, you will see the list of all the topics discussed so far in this forum. To participate in a discussion simply click on the topic in question.

V1.2 Discussion forum Know yo	ur epidemic		¢ -
Add a new discussion topic			
Discussion	Started by	Replies	Last post
DR TB short course regimen of 9 months	Waliullah Hatam Khan	7	Taofeekat Taiwo Al Sun, 25 Feb 2018, 6:32 AM
Summary week 1	😝 Tom Decroo	2	Tom Decroo Fri, 2 Mar 2018, 9:04 AM
Myanmar Data	Ko Ko Aung	2	Ko Ko Aung Wed, 21 Feb 2018, 6:40 AM
Data From Italy	Gianluca Granà	0	Gianluca Granà Thu, 1 Mar 2018, 5:17 PM
Swaziland experience	Daniel Meressa Kokebu	2	Taofeekat Taiwo Al Mon, 26 Feb 2018, 1:32 PM
Indicators for an MDR TB program	Taofeekat Taiwo Ali	0	Taofeekat Taiwo Al Wed, 28 Feb 2018, 4:14 AM
Data from Nepal	👮 Deebya Raj Mishra	0	Deebya Raj Mishra Tue, 27 Feb 2018, 4:05 AM
TB diseases burden: Measures of TB burden in a country	Yves Habimana Mucyo	0	Yves Habimana Mucyo Mon, 26 Feb 2018, 8:08 AM
Swazialnd expreinece	Taofeekat Taiwo Ali	0	Taofeekat Taiwo Ali Sun, 25 Feb 2018, 6:08 PM

There are two ways to post your questions and comments in a forum.

You can either start a new topic (1), or answer an existing one (2). (1) Start a new discussion by 'adding a new discussion topic'




Go to "Add a new discussion topic" on the forum (as shown before).

Put the name of the topic you wish to introduce in the "subject" box (1). Try to choose a name that will be understood by all. Then type your text in the main box.

When it is done, scroll down the page and click post to forum.

(2) Below the text box, you can add an attachment if needed by browsing for a document



(2) Reply to an existing topic


If you wish to answer or comment on an ongoing topic in the forum you can click on 'reply' and then post your comment in the text box that appears (see picture below).

Export whole discussion to portfolio	Display replies in nested form			
	Move this discussion to		Pin	
	Move			
Indicators for an MDR TB progra by Taofeekst Taiwo Ali - Wednesd				
new TB cases and 25% among pre indicators was equally low: only 1 (unpublished NTBLCP report, 2013	URR TB burden with an estimated in viously treated TB cases). TB case de 586 cases were laboratory confirmed 8) of which 78% were enrolled on sec y increased from 61% among 2016 c	tection in 2016 was only 24%, he . In 2017, Nigeria diagnosed only ond line drugs. This shows fairly	nce achievem 9% of estima moderate cas	ent of MDR/RR TB ted 20,000 MDR/RR cases scade loss. However
	ency in laboratory and clinical care pr (BMU) at the local govt. level to the Si			
Suggested indicators for MDR TB	program:			
Impact indicator: MDR/RR TB Inci	dence			
Proportion of new TB patients with	th MDR/RR TB (New TB patients with	MDR-RR TB / All forms of TB)		
Coverage Indicator: Lab diagnosis	access			
Percentage of TB patients accessiv	ng gene expert (Total no of patients t	ested using gene expert/Total T8	cases notifie	d)
Coverage Indicator: Treatment ac	(ess			
Proportion of MDR/RR TB cases no MDR/RR TB notified)	otified that began second line treatm	ent (No of MDR/RR T8 that bega	second line	treatment/Total no of
Outcome indicator: Treatment su	ccess rate (TSR)			
	sfully treated (No of bacteriologically of bacteriologically confirmed MDR/R		olied on SLD	with treatment success i.e
Laboratory performance:				
Proportion of functional laborator	ies (gene expert/culture) that are fun	ctional		
Proportion of laboratories showin institutionalized.	g adequate quality accessment perfo	mance (routine external quality	assurance m	easures should be
		Dermalink	Delete	Reply Export to portfolio
Pata from Nenal				Associated association &

How to use the submit your assignment?

W0.3.E Exercise: Submit an Grading summary	n assignment		0 -			
Hidden from students		No				
Participants		21				
Submitted		11				
Needs grading		11				
	View all submissions Grade					
ubmission status						
Attempt number	This is attempt 1 (1 attempts allowed).					
Submission status	No attempt					
Grading status	Not graded					
Last modified						
Submission comments	Comments (0)					
	Add submission					
	You have not made a submission yet					
			Click		the	the add
			butto	r	n	n
			Natte			





(1) Drag and dropyour file(2) Save changes


DO YOU WANT TO STORE THE LECTURES OFFLINE. PLEASE USE THE APPS FOR YOUR COMPUTER OR ANY MOBILE DEVICE?


Moodle Desktop (only for Windows 7, 8 and Mac)


This application will allow you to save course content on your computer and access it without access to the internet (offline).


You can download the application for your Mac or Windows from this link <u>https://download.moodle.org/desktop/</u>


After finishing the installation, please type the address of our course page http://mdrtb.itg.be












Click here to access the content


Click to access the different weeks

	Moodle Desktop	
K Back	Online module DR-TB course 2018	:
All sections		
Welcome to the course!		
Week 0		
Week 1		
Week 2		
Week 3		
Week 4		
Week 5		
Week 6		
Week 7		
Week 8		



Moodle Mobile Phones and Tablets (Android and Apple iOS)

This application will allow you to save course content on your mobile phone or tablet and access it without access to the internet (offline). Download the Moodle mobile app for your smartphone or tablet from iTunes store or Google Play and install it



•II Orang	ge B 🤝	2		10:52		3	¶ ¥ 43	% 🛄 🔸				
		Co	nneo	et to	Mood	lle		?				
Ple No wit	ase er	nter th t it mig app.	e URI ght no	of yo t be c	our Mo onfigu	odle : ired to	e site.	4	Type t	RL of	DR	
				el.								
			C	onneo	et!							
			C	onneo	ot!				J			
	~		C	onneo	st!			Done				
qv	v e	e r			ett / L	1 [r i o					
q v a	v e s	e r d				ı j						
			•	t y	/ι		i o	p				

The instructions on how to access the course and content are the same as for the Desktop app